Neogenomics Stock Performance
| NEO Stock | USD 17.90 0.27 1.49% |
NeoGenomics has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.25, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NeoGenomics will likely underperform. NeoGenomics right now secures a risk of 2.56%. Please verify NeoGenomics maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to decide if NeoGenomics will be following its current price movements.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in NeoGenomics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, NeoGenomics may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Actual Historical Performance (%)
One Day Return (1.41) | Five Day Return 4.55 | Year To Date Return 13.92 | Ten Year Return 327.53 | All Time Return 4.1 K |
Last Split Factor 1:100 | Last Split Date 2003-04-16 |
1 | NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 | 10/15/2024 |
2 | NeoGenomics Inc Shares Up 4.16 percent on Nov 1 | 11/01/2024 |
3 | NeoGenomics, Inc. Q3 2024 Earnings Call Transcript | 11/07/2024 |
4 | Disposition of 11336 shares by Hannah Alison L. of NeoGenomics subject to Rule 16b-3 | 11/15/2024 |
5 | NeoGenomics general counsel sells 79,475 in stock | 11/19/2024 |
6 | Segall Bryant Hamill LLC Has 27.93 Million Holdings in NeoGenomics, Inc. | 11/20/2024 |
7 | NeoGenomics Inc Shares Up 4.09 percent on Nov 22 | 11/22/2024 |
8 | NEO Battery Materials Announces Corporate Webinar on Silicon Anode Technology Developments Pathway to Commercialization | 11/25/2024 |
9 | Disposition of 6224 shares by Warren Stone of NeoGenomics subject to Rule 16b-3 | 11/29/2024 |
10 | NEO SPACE GROUP TO ACQUIRE UP42 EARTH OBSERVATION DIGITAL PLATFORM FROM AIRBUS | 12/03/2024 |
11 | Brokerages Set NeoGenomics, Inc. PT at 20.25 | 12/05/2024 |
12 | Disposition of 11746 shares by Sherman Jeffrey Scott of NeoGenomics subject to Rule 16b-3 | 12/06/2024 |
13 | NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting | 12/09/2024 |
| Begin Period Cash Flow | 263.2 M |
NeoGenomics |
NeoGenomics Relative Risk vs. Return Landscape
If you would invest 1,640 in NeoGenomics on September 13, 2024 and sell it today you would earn a total of 150.00 from holding NeoGenomics or generate 9.15% return on investment over 90 days. NeoGenomics is generating 0.1692% of daily returns assuming volatility of 2.5626% on return distribution over 90 days investment horizon. In other words, 22% of stocks are less volatile than NeoGenomics, and above 97% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
NeoGenomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeoGenomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeoGenomics, and traders can use it to determine the average amount a NeoGenomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.066
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NEO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.56 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average NeoGenomics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeoGenomics by adding it to a well-diversified portfolio.
NeoGenomics Fundamentals Growth
NeoGenomics Stock prices reflect investors' perceptions of the future prospects and financial health of NeoGenomics, and NeoGenomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeoGenomics Stock performance.
| Return On Equity | -0.0838 | ||||
| Return On Asset | -0.0276 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 2.58 B | ||||
| Shares Outstanding | 128.36 M | ||||
| Price To Earning | 272.37 X | ||||
| Price To Book | 2.60 X | ||||
| Price To Sales | 3.62 X | ||||
| Revenue | 591.64 M | ||||
| Gross Profit | 187.9 M | ||||
| EBITDA | (17.61 M) | ||||
| Net Income | (87.97 M) | ||||
| Cash And Equivalents | 465.95 M | ||||
| Cash Per Share | 3.70 X | ||||
| Total Debt | 611.68 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 7.09 X | ||||
| Cash Flow From Operations | (1.95 M) | ||||
| Earnings Per Share | (0.61) X | ||||
| Market Capitalization | 2.33 B | ||||
| Total Asset | 1.68 B | ||||
| Retained Earnings | (247.06 M) | ||||
| Working Capital | 500.51 M | ||||
| Current Asset | 82.36 M | ||||
| Current Liabilities | 40.06 M | ||||
About NeoGenomics Performance
By examining NeoGenomics' fundamental ratios, stakeholders can obtain critical insights into NeoGenomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that NeoGenomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 25.41 | 17.59 | |
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.07) | (0.06) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.09) |
Things to note about NeoGenomics performance evaluation
Checking the ongoing alerts about NeoGenomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeoGenomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 591.64 M. Reported Net Loss for the year was (87.97 M) with profit before taxes, overhead, and interest of 187.9 M. | |
| NeoGenomics has about 465.95 M in cash with (1.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7. | |
| NeoGenomics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting |
- Analyzing NeoGenomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeoGenomics' stock is overvalued or undervalued compared to its peers.
- Examining NeoGenomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeoGenomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeoGenomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeoGenomics' stock. These opinions can provide insight into NeoGenomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.